Claire Reiss insider trades: Biocept (BIOC) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Claire reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 19, 2016 | BIOC | ↑ Buy | 227,272 | $1.10 | $250K | By trusts | Oct 21, 2016 (2d) |
| May 4, 2016 | BIOC | ↑ Buy | 614,273 | $1.00 | $614K | By trusts | May 5, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Claire Reiss's insider trades
Claire Reiss is a 10% owner of Biocept (BIOC). Since May 4, 2016, Claire has reported 2 open-market purchases worth $864K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BIOC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.